Autologous Bone Graft Substitute Composition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current alternatives to autografts for spinal fusion and bone defect treatments face challenges such as increased surgical risks, pain, limited availability, and safety concerns associated with high doses of bone morphogenetic proteins (BMPs), leading to a need for improved compositions that can promote robust new bone growth without these drawbacks.

Innovation Solution

An Autologous Bone Graft Substitute composition comprising autologous blood, osteogenic bone morphogenetic proteins (BMP-6, BMP-2, BMP-7, etc.), and a compression-resistant matrix like hydroxyapatite or tri-calcium phosphate, which forms a coagulum gel for sustained bone growth promotion, reducing the need for invasive procedures and minimizing immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If autograft is used for spinal fusion and bone defect treatment, then new bone growth is promoted effectively, but surgical risks, pain, and infection risk increase due to second incision

Engineering Contradiction:

Improvebone growth promotionVSAvoidsurgical risks and infection risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent creates an artificial bone graft substitute that copies the essential functions of autograft by incorporating BMP-2 protein and bone marrow cells into a collagen matrix, achieving bone growth promotion without requiring actual autograft harvesting

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent uses a collagen matrix as an intermediary carrier to deliver BMP-2 and bone marrow cells to the bone defect site, replacing the need for autograft while maintaining the osteogenic function

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If alternative bone graft substitutes are used instead of autograft, then surgical risks are reduced, but bone growth promotion capability is insufficient

Engineering Contradiction:

Improvesurgical risksVSAvoidbone growth promotion

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent creates a composite bone graft substitute combining collagen matrix, BMP-2 protein, and bone marrow cells, integrating multiple functional components to achieve both safety and effective bone growth promotion

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent merges three key osteogenic elements (collagen scaffold, BMP-2 growth factor, and bone marrow cells) into a single composite preparation to enhance bone growth capability while avoiding autograft risks

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If high doses of BMPs are used to promote bone growth, then bone formation is enhanced, but safety concerns and harmful effects increase

Engineering Contradiction:

Improvebone formationVSAvoidsafety concerns

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent utilizes the patient's own bone marrow cells as a self-service component that naturally supports and regulates BMP-2 activity, enabling effective bone formation at lower BMP-2 doses with reduced safety concerns

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent changes the dosing parameter by using lower concentrations of BMP-2 (0.1-10 µg/mL) combined with bone marrow cells, achieving effective bone formation while reducing the harmful effects associated with high BMP doses

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively induces new bone formation with lower BMP doses, avoiding inflammatory responses and foreign-body reactions, and can be administered non-invasively, overcoming limitations of existing bone graft substitutes by providing a biocompatible, sustained release of BMPs for enhanced bone repair.

Implementation Method 1

the autologous blood forms a coagulum gel comprising the osteogenic bone morphogenetic protein within fibrin-meshwork

Methodology Applied

Scientific EffectCoagulation: Coagulation

Data Source

PatentEP3697459B1Autologous bone graft substitute

Publication Date: 2022.10.26 GENERA ISTRAZIVANJA D O O

Figure 1~1B
Figure 2A~2F
Figure 3A~3D

AI summary

The present invention relates to an Autologous Bone Graft Substitute composition (ABGS) for inducing new bone formation, promoting bone growth and treating of bone defect, a preparation method of the Autologous Bone Graft Substitute composition, and a kit for preparing the Autologous Bone Graft Substitute composition of implant. In a particular aspect, the invention relates to an injectable/extrudable/implantable Autologous Bone Graft Substitute composition for use in treatment of bone defects, inducing new bone formation and promoting bone growth for bone fracture healing, spinal fusions and to repair bone defects in bone reconstructive procedures of orthopedic and oral maxillofacial-dental surgeries.